Muscle Loss on a GLP-1: Why It Matters for Women, and How to Protect It

The short version

When the scale drops fast on a GLP-1, not all of what leaves is fat. A meaningful share is skeletal muscle — the tissue that lets you carry a toddler, get up off the floor, keep your metabolism humming, and stay strong into your later decades. Across the randomized trials, roughly a quarter to a third of the weight lost on these drugs is lean mass rather than fat¹. That's not a reason to skip treatment; the same trials show muscle is largely defensible if you plan for it. But it matters more for women — especially women over 40 heading into menopause — because that's exactly when muscle is already slipping. This guide is specifically about muscle: why it counts, how much you lose, and the two levers with real evidence behind them. (For the closely related bone-density question, see our companion guide on bone density and lean mass on GLP-1s.)

Muscle is not just a number on a body scan

It's easy to treat "lean mass" as an abstraction. It isn't. Skeletal muscle is what generates strength and power, stabilizes your joints, and does a large share of your day-to-day glucose disposal — it's metabolically active tissue, so losing it can quietly lower the number of calories you burn at rest. Lose too much and you feel it as weakness, worse stamina, and, over years, a higher risk of frailty and falls. The goal of weight loss for a mother isn't just a smaller body; it's a stronger, more capable one. That reframes muscle from a side note into something you actively defend.

How much muscle you actually lose — and the trials were mostly women

The cleanest figures come from body-composition data. A 2026 systematic review of the incretin trials found that lean mass made up about 25–39% of total weight lost — roughly 35% with semaglutide and 25% with tirzepatide — and, tellingly, that lifestyle-only weight loss showed a similar proportion¹. In other words, this is mostly a feature of losing weight quickly, not a toxic effect unique to the drug. A dedicated DXA substudy of the SURMOUNT-1 tirzepatide trial — a group that was 73% female — measured it directly: of the roughly 21% body weight lost, about three-quarters was fat and a quarter was lean mass². Because that trial population was overwhelmingly women, those proportions describe you, not a male average.

Why this lands harder for women over 40

Here's the part general "muscle loss on Ozempic" articles miss. Women are already losing muscle at exactly the life stage when many start a GLP-1. Across the menopausal transition, muscle mass falls measurably — a 2026 review of the human data found reductions of about 2.5% in perimenopausal and 5.7% in postmenopausal women compared with premenopausal women, tied to the drop in estrogen⁷. Layer a rapid, GLP-1-driven weight loss on top of an already-declining muscle baseline and the arithmetic is obvious: the tissue you can least afford to lose is the tissue under the most pressure. This is the same reason our guide to GLP-1s through perimenopause and menopause treats strength as a first-order goal rather than a bonus.

Lever one: resistance training (and yes, even in a calorie deficit)

The single best-evidenced defense is lifting. A 2026 meta-analysis of calorie-restriction trials found that adding exercise preserved fat-free mass strikingly well — exercise prevented nearly half (about 46%) of the fat-free-mass loss that occurred with dieting alone, and strength or mixed training gave the biggest benefit (on the order of +0.9 to +1.2 kg of fat-free mass retained)³. When a GLP-1 is the tool doing the weight loss, the logic carries over: in a trial combining exercise with a GLP-1, the combination roughly doubled the reduction in body-fat percentage compared with either the drug or exercise alone⁵.

One honest nuance that should change how you think about it: in a calorie deficit you may not build much new muscle, but you can still get stronger. A meta-analysis found that training in an energy deficit blunts lean-mass gains yet leaves strength gains essentially intact⁴. So don't wait until "after" to start lifting, and don't judge it by the scale — judge it by whether the weights are going up. Two to three sessions a week hitting the major movements is the habit that matters.

Lever two: protein, even when the drug kills your appetite

The catch with a GLP-1 is that it works by cutting appetite — which is exactly what makes protein hard to hit. Muscle needs the raw material, and higher-protein eating during weight loss is consistently linked to better preservation of lean mass while also supporting fullness⁶. In practice that means aiming well above the bare-minimum 0.8 g/kg RDA — many clinicians target something in the 1.2–1.6 g/kg range while a patient is actively losing weight⁶ — and treating protein as the first thing on the plate at each meal rather than whatever's left after a few bites. When appetite is genuinely small, front-loading protein (and leaning on easy sources like Greek yogurt, eggs, fish, or a shake) does more for your muscle than any supplement gimmick.

Putting it together

Muscle loss on a GLP-1 is real, it's mostly a function of how you lose weight, and it's largely preventable with two unglamorous habits: lift a few times a week, and eat enough protein even when you're not hungry. What you want from a program is one that plans for this from the start — that talks about pace, protein, and strength rather than only maximizing the number on the scale. That's the kind of clinical judgment our Metabolic-Fit Score methodology rewards, and one reason clinician-led options such as CoreAge Rx sit near the top of our ranking of GLP-1 providers for women. If a slower, steadier trajectory appeals to you as a way to protect muscle, our guide to microdosing GLP-1s for mothers is worth a look. This article is educational only and not medical advice; decisions about training, protein, and GLP-1 treatment belong with clinicians who know your history.